[Tiapride in the treatment of irreversible tardive dyskinesia--initial experiences].
Twelve patients on a chronic psychiatric ward with NL-induced permanent TD were treated with 300 mg tiapride daily for at least 3 weeks. Clinical assessment of TD was performed with AIM-Scale before and after 3 weeks' therapy, showing a significant effect of treatment. These preliminary findings were controlled in a blind study, showing again a significant therapeutic effect of tiapride.
D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy*; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D001549:Benzamides; D013976:Tiapamil Hydrochloride
Tiaprid in der Behandlung irreversibler tardiver Dyskinesien--erste Erfahrungen.